Recent advances on nano delivery of Helix mucus pharmacologically active components

International Journal of Nano Dimension

مقاله 1، دوره 7، شماره 3، آبان 2016، صفحه 181-185   

نوع مقاله: Review

شناسه دیجیتال (DOI): 10.7508/ijnd.2016.03.001

نویسنده

Raffaele Conte^*

Institute of Biosciences and BioResources, National Research Council, Via Pietro Castellino, 111, Naples, Italy

چکیده

Bioactive products from snail slime of “Helix” specie have potential applications in preventing and/or treating several human diseases and in cancer diagnosis. However, the poor pharmacokinetics characteristics of these natural compounds limit their use. Nanotechnology offers promising solutions for the enhanced formulation of these molecules through the synthesis of nanosized drug delivery systems. These vectors are characterized by facilitated transport across the biological barriers, enhanced bioavailability, targeted delivery and the capacity to protect sensitive compounds from biological and environmental degradation. Overall, this review focus on the description of bioactive natural substances derived from snails belonging to the genus helix and their successfully combinations with nanosized vectors.

کلیدواژه‌ها

Allantoin؛ Helicidine؛ Helix pomatia agglutinin؛ Helix؛ nanoparticles؛ Nanotechnology؛ Solid lipid nanoparticles

مراجع

[1] Gabor J. J. M. , Hornyak L., Dutta J., (2008), Fundamentals of nanotechnology. Boca Raton, FL: Taylor & Francis Group, CRC Press.

[2] Silva G. A., (2004), Introduction to nanotechnology and its applications to medicine. Surg. Neurol. 61: 216-220.

[3] Groneberg D. A., Giersig M., Welte T., Pison U., (2006), Nanoparticle-based diagnosis and therapy. Curr. Drug. Targets. 7: 643-648.

[4] Barker G. M., (2001), The biology of terrestrial molluscs. CABI Pub.

[5] Cuttelod A., (2011), European red list of non marine molluscs. IUCN Publications Services.

[6] Bonnemain B., (2005), Helix and drugs: Snails for western health care from antiquity to the present. Evid Based Complement Alternat Med. 2: 25-28.

[7] Quevauviller A., Garcet S., (1953), The mucus of Helix pomatia L.; preparation, composition, therapeutic and pharmacodynamic properties, biologic assay. Rev. Pathol. Gen. Physiol. Clin. 53: 653-658.

[8] El Mubarak M. A., Lamari F. N., Kontoyannis C., (2013), Simultaneous determination of allantoin and glycolic acid in snail mucus and cosmetic creams with high performance liquid chromatography and ultraviolet detection. J. Chromatogr. A. 1322: 49-53.

[9] Ulhôa Araújo L., Grabe-Guimarães A., Furtado Mosqueira V. C., Martins Carneiro C., Silva-Barcellos N. M., (2010), Profile of wound healing process induced by allantoin. Acta Cirúrgica. Brasileira. 25: 7-10.

[10] Thornfeldt C., (2005), Cosmeceuticals Containing Herbs: Fact, Fiction, and Future. Dermatologic. Surg. 31: 145-149.

[11] Pons F., Michelot R., Mayer M., Frossard N., (2008), The bronchorelaxant effect of helicidine, a Helix pomatia extract, Involves prostaglandin E2 release. Pharmaceutical Biology. 36: 7-11.

[12] Dwek M.V., Streets A. J., Brooks S. A., Adam E., Titcomb A., Woodside J. V., (2001), Helix pomatia agglutinin lectin-binding oligosaccharides of aggressive breast cancer. Int. J. Cancer. 95: 155-159.

[13] Brooks S. A., Leathem A. J., (1991), Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour. Lancet. 338 : 71-74.

[14] Rambaruth N. D., Greenwell P., Dwek M. V., (2012), The lectin Helix pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human breast cancer. Glycobiology. 22: 839-848.

[15] Sanchez J. F., Lescar J., Chazalet V., Audfray A., Gagnon J., Alvarez R., (2006), Biochemical and structural analysis of Helix pomatia agglutinin. A hexameric lectin with a novel fold. J. Biol. Chem. 281: 20171-20180.

[16] Pan A., Chen M., Chowdhury R., Wu J. H., Sun Q., Campos H., (2012), Alpha-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am. J. Clin. Nutr. 96: 1262-1273.

[17] Conte R., (2015), Heliciculture: Purpose and economic perspectives in the European community. IST Journal. Spring 2015.

[18] Kubik T., Bogunia-Kubik K., Sugisaka M., (2005), Nanotechnology on duty in medical applications. Curr. Pharmac. Biotechnol. 6: 17-22.

[19] Svetlichny G., Kulkamp-Guerreiro I. C., Cunha S. L., Silva F. E., Bueno K., Pohlmann A. R., (2015), Solid lipid nanoparticles containing copaiba oil and allantoin: development and role of nanoencapsulation on the antifungal activity. Pharmazie. 70: 155-164.

[20] Dumych T., Lutsyk M., Banski M., Yashchenko A., Sojka B., Horbay R., (2014), Visualization of melanoma tumor with lectin-conjugated rare-earth doped fluoride nanocrystals. Croatian Medical Journal. 55: 186-194.

[21] Banski M., Podhorodecki A., Misiewicz J., (2013), NaYF4 nanocrystals with TOPO ligands: Synthesis-dependent structural and luminescent properties. Phys. Chem. Chem. Phys. 15: 19232-19241.